Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Braz. j. med. biol. res ; 49(7): e5300, 2016. tab, graf
Article Dans Anglais | LILACS | ID: lil-785056

Résumé

The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main reason (38.5%). Risk factors for treatment discontinuation were higher comorbidity index (OR=1.85, CI=1.05-3.25) for BOC, and higher bilirubin count (OR=1.02, CI=1.01-1.04) and lower BMI (OR=0.98, CI=0.96-0.99) for TVR. Severe anemia occurred in 35 (17.2%) patients. Risk factors for this outcome were lower estimated glomerular filtration rate (eGFR; OR=0.95, CI=0.91-0.98) for patients treated with TVR, and higher comorbidity index (OR=2.21, CI=1.04-4.67) and ribavirin dosage (OR=0.84, CI=0.72-0.99) for those treated with BOC. Fifty-five (57.3%) patients treated with TVR and 15 (27.3%) patients treated with BOC achieved sustained virological response (SVR). Among patients who received TVR and interrupted treatment due to AE (n=19), only 26.3% (n=5) achieved SVR (P=0.003). Higher number of comorbidities, lower eGFR and advanced liver disease are associated with severe anemia and early treatment cessation, which may compromise SVR achievement.


Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Jeune adulte , Anémie/étiologie , Hépatite C chronique/traitement médicamenteux , Oligopeptides/administration et posologie , Proline/analogues et dérivés , Inhibiteurs de protéases/administration et posologie , Antiviraux/administration et posologie , Débit de filtration glomérulaire , Hépatite C chronique/complications , Hépatite C chronique/virologie , Interféron alpha/administration et posologie , Modèles logistiques , Oligopeptides/effets indésirables , Polyéthylène glycols/administration et posologie , Proline/administration et posologie , Proline/effets indésirables , Études prospectives , Inhibiteurs de protéases/effets indésirables , Protéines recombinantes/administration et posologie , Ribavirine/administration et posologie , Facteurs de risque , Indice de gravité de la maladie , Statistique non paramétrique , Réponse virologique soutenue , Facteurs temps , Échec thérapeutique
2.
Braz. j. med. biol. res ; 49(11): e5504, 2016. tab, graf
Article Dans Anglais | LILACS | ID: lil-797884

Résumé

Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contraindications and can cause significant adverse events, which can reduce adherence and impair SVR rates. SOF plus RBV for 24 weeks is another treatment option, with SVR rates of 82–96% among patients without cirrhosis and 62–92% among those with cirrhosis. Finally, SOF plus DCV provides 94–97% SVR rates in non-cirrhotic patients, but 59–69% in those with cirrhosis. The addition of RBV to the regimen of SOF plus DCV increases the SVR rates in cirrhotic patients above 80%, and extending treatment to 24 weeks raises SVR to 90%. The ideal duration of therapy is still under investigation. For cirrhotic patients, the optimal duration, or even the best regimen, is still uncertain. Further studies are necessary to clarify the best regimen to treat HCV genotype 3 infection.


Sujets)
Humains , Antiviraux/usage thérapeutique , Hépatite C chronique/traitement médicamenteux , Hépatite C/génétique , Cirrhose du foie/étiologie , Association de médicaments , Génotype , Hépatite C chronique/complications , Hépatite C chronique/génétique , Imidazoles/usage thérapeutique , Interféron alpha/usage thérapeutique , Ribavirine/usage thérapeutique , Sofosbuvir/usage thérapeutique
3.
Braz. j. med. biol. res ; 49(9): e5432, 2016. tab, graf
Article Dans Anglais | LILACS | ID: lil-788944

Résumé

Although long regarded as the gold standard for liver fibrosis staging in chronic hepatitis C (CHC), liver biopsy (LB) implies both the risk of an invasive procedure and significant variability. The aim of this study was to evaluate the diagnostic performance for transient elastography (TE) and aspartate aminotransferase to platelet index (APRI) used alone and in combination compared to liver biopsy and to analyze false positive/negative results. Patients with CHC, and no previous clinical diagnosis of cirrhosis were enrolled to undergo liver biopsy, TE and APRI. A total of 182 adult patients with a median age of 55 years and median body mass index of 26.71 kg/m2 were analyzed. On LB, 56% of patients had significant levels of fibrosis (METAVIR F≥2) and 28% had advanced fibrosis (F3/F4). The strongest performance for both tests was observed for exclusion of advanced fibrosis with good negative predictive values (89 and 86%, respectively). Low necroinflammatory activity on LB was associated with false negative TE. False positives were associated with NASH and smaller LB fragments. Correlation between APRI and Fibroscan for F≥2 was 100% and 84% for F≥3 and remained high in both false negative and false positive instances, correctly identifying F<2 in 71% of cases and F<3 in 78% (and potentially foregoing up to 84% of LB). We concluded that low individual performance indicators could be attributable to limitations of LB. Poorer differentiation of lower levels of fibrosis is a known issue for LB and remains so for noninvasive tests. Good predictability is possible, however, for advanced fibrosis.


Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Jeune adulte , Alanine transaminase/sang , Aspartate aminotransferases/sang , Imagerie d'élasticité tissulaire , Hépatite C chronique/complications , Cirrhose du foie/diagnostic , Études transversales , Faux négatifs , Faux positifs , Hépatite C chronique/anatomopathologie , Cirrhose du foie/étiologie , Cirrhose du foie/anatomopathologie , Numération des plaquettes , Valeur prédictive des tests , Études prospectives
SÉLECTION CITATIONS
Détails de la recherche